A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Miao, Miao; Wu, Depei; Xie, Shuangfeng; Hong, Min; Chang, Chunkang; Yu, Li; Gao, Sujun; Li, Yan; Li, Yuhua; Zhu, Zunmin; Tang, Baolin; Li, Bing‐Zong; Yang, Haiping; Wang, Jishi; Ling, Qin; Fu, Rong; Li, Fēi; Ma, Liangming; Liu, Qifa; Du, Xin; Jiang, Zhongxing; Li, Zhenyu; Liu, Aijun; Tong, Hongyan; Ma, Jun; Liu, Li; Liu, Qingchi; Xu, Yajing; Zhou, Hui; Wang, Yan; Chen, Jianlin; Niu, Ziru; Chen, Mingxia; Xiao, Zhijian

doi:10.1182/blood-2022-155901

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…423,424 The combination of decitabine and pembrolizumab induced better response in patients with relapsed AML, with transcriptional signs of immune activation. 425 Other combinations of HMAs and ICIs also show good safety and preliminary anti-tumor effects in patients with hematological malignancies in clinical trials [426][427][428][429] (Supplementary Table 5). Regarding solid tumors, although the preclinical and some early clinical results using the combination of PD-1 blockade and HMAs are highly promising, [430][431][432] most clinical data has been disappointing.…”

Section: Nucleus Cytoplasmmentioning

confidence: 99%

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin,

Li,

Zhang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of novel immunoregulatory targets and mechanisms are being revealed, with relevant therapies promising to improve clinical immunotherapy in the foreseeable future. Therefore, comprehending the larger picture is important. In this review, we analyze and summarize the current landscape of preclinical and translational mechanistic research, drug development, and clinical trials that brought about next-generation pharmacological immunoregulatory anti-cancer agents and drug candidates beyond classical immune checkpoint inhibitors. Along with further clarification of cancer immunobiology and advances in antibody engineering, agents targeting additional inhibitory immune checkpoints, including LAG-3, TIM-3, TIGIT, CD47, and B7 family members are becoming an important part of cancer immunotherapy research and discovery, as are structurally and functionally optimized novel anti-PD-(L)1 and anti-CTLA-4 agents and agonists of co-stimulatory molecules of T cells. Exemplified by bispecific T cell engagers, newly emerging bi-specific and multi-specific antibodies targeting immunoregulatory molecules can provide considerable clinical benefits. Next-generation agents also include immune epigenetic drugs and cytokine-based therapeutics. Cell therapies, cancer vaccines, and oncolytic viruses are not covered in this review. This comprehensive review might aid in further development and the fastest possible clinical adoption of effective immuno-oncology modalities for the benefit of patients.

show abstract

Section: Nucleus Cytoplasmmentioning

confidence: 99%

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin,

Li,

Zhang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…288,289 CD47-targeted therapies, including IBI188 and HX009, are in clinical trials. 290 CD123, highly expressed on cancer cells, particularly in hematological malignancies, is targeted by Talacotuzumab (JNJ-56022473) and IMGN632. 291 TAGraxofusp, an IL-3Rα-targeted therapy, is approved for blastic plasmacytoid dendritic neoplasms (BPDCN).…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…CD47 is overexpressed on cancer cells, including CSCs, promoting immune evasion 288,289 . CD47‐targeted therapies, including IBI188 and HX009, are in clinical trials 290 . CD123, highly expressed on cancer cells, particularly in hematological malignancies, is targeted by Talacotuzumab (JNJ‐56022473) and IMGN632 291 .…”

Section: Targeting Csc Signaling Pathwaysmentioning

confidence: 99%

Cancer stem cells: Signaling pathways and therapeutic targeting

Talukdar,

Srivastava,

Sahoo

et al. 2023

MedComm – Oncology

View full text Add to dashboard Cite

Cancer stem cells (CSCs) constitute a minority cell population characterized by unbounded proliferative potential in both solid and hematological cancers. Despite sharing key stem cell attributes, CSCs possess unique traits, including the initiation and propagation of tumors and resistance to conventional therapies. The purpose of this review is to delve into the origins and fundamental characteristics of CSCs, emphasizing their role in tumor growth and metastasis. The focus extends to unraveling cellular signaling pathways driving oncogenic processes and understanding aberrant cellular crosstalk crucial for targeted cancer therapies. Beginning with an exploration of CSC properties and behavior, we progress to dissecting the cellular signaling network that fuels oncogenic pathways. The discussion spans the inception of CSCs, their survival strategies, and adaptation to new environments. We then transit to recent therapeutic advancements targeting CSCs, culminating in an exploration for precise therapeutic targeting. This review henceforth, underscores the vital significance of comprehending CSCs in cancer progression and treatment resistance. By unraveling the complex signaling pathways and survival mechanisms unique to CSCs, it paves the way for targeted therapeutic strategies that hold immense promise in enhancing cancer treatment efficacy while minimizing collateral damage.

show abstract